Fluc-eGFP mRNA, Dual-Reporter for Protein Expression
In recent years, mRNA vaccines and drugs have received widespread attention around the world. Areterna LLC is proud to introduce Fluc-eGFP mRNA (Catalog number: 11013-CAP), a cutting-edge tool to accelerate your mRNA research. This mRNA encodes both eGFP and...dsRNA: an unwanted byproduct from mRNA IVT
In vitro transcription (IVT) remains the predominant method for large-scale mRNA synthesis due to its efficiency and scalability. However, a significant challenge associated with IVT is the residual double-stranded RNA (dsRNA) produced as a by-product. This dsRNA can...Why Co-Transcriptional Capping
In-vitro transcription (IVT) is a reactor-based scheme to manufacture RNA where cell-derived impurities or adventitious contaminants can be avoided thus making the manufacturing process GMP-friendly. The IVT reaction is often carried out at 37°C for 2...Enzymatic Capping: Process, Pros, and Cons
We have discussed the evolution of cap analogs and the new generation of fine-tuned cap analogs for different applications. Generally, there are two ways of capping mRNA produced from an IVT reaction. One way is co-transcriptionally capping where a cap analog is added...Areterna’s Caps and NTPs as Evaluated by a Customer
Areterna offers Cap Analogs, NTPs, and Modified NTPs for mRNA synthesis. Our products have been tested and accepted by over 200 companies worldwide. One of these companies shared with us how they decided to use our products.